[{"NetIncomeLoss_1_Q2_USD":-6152000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":6510000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2_Q2_pure":0.849,"InterestPaidNet_2_Q2_USD":1020000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-45000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2_Q2_pure":0.011,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-115854000.0,"DebtInstrumentInterestRateDuringPeriod_2_Q2_pure":0.0807,"DebtInstrumentInterestRateDuringPeriod_1_Q2_pure":0.0807,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_Q2_shares":266724.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":72000.0,"AssetsCurrent_0_Q2_USD":277615000.0,"OtherNoncashIncomeExpense_2_Q2_USD":-258000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":8429329.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":452000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_2_Q2_USD":-174000.0,"OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1_Q2_USD":-45000.0,"EquitySecuritiesFvNi_0_Q2_USD":35280000.0,"CommonStockSharesIssued_0_Q2_shares":46141454.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":285002000.0,"Assets_0_Q2_USD":359788000.0,"ShareBasedCompensation_2_Q2_USD":9859000.0,"CommonStockCapitalSharesReservedForFutureIssuance_0_Q2_shares":10674126.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_Q2_USD":14.71,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1_Q2_USD":12.84,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":5265000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":12545000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":23652000.0,"MarketableSecuritiesCurrent_0_Q2_USD":167032000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"ResearchAndDevelopmentExpense_1_Q2_USD":25309000.0,"EarningsPerShareBasic_2_Q2_USD":-0.79,"EarningsPerShareBasic_1_Q2_USD":-0.13,"InterestPayableCurrentAndNoncurrent_0_Q2_USD":200000.0,"EquitySecuritiesFvNiUnrealizedGainLoss_2_Q2_USD":-6364000.0,"EquitySecuritiesFvNiUnrealizedGainLoss_1_Q2_USD":4325000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":46007892.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":46116175.0,"ProceedsFromStockPlans_2_Q2_USD":873000.0,"AccountsReceivableNetCurrent_0_Q2_USD":9160000.0,"CommonStockValue_0_Q2_USD":46000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":2411000.0,"IncreaseDecreaseInEmployeeRelatedLiabilities_2_Q2_USD":-2313000.0,"CommonStockSharesAuthorized_0_Q2_shares":300000000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":1787000.0,"InvestmentIncomeNonoperating_2_Q2_USD":372000.0,"InvestmentIncomeNonoperating_1_Q2_USD":175000.0,"IncreaseDecreaseInDeferredCharges_2_Q2_USD":-2092000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-36685000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-6197000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":1742000.0,"OtherAssetsNoncurrent_0_Q2_USD":2626000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":56392000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":571883000.0,"Liabilities_0_Q2_USD":52288000.0,"SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_0_Q2_shares":4445.0,"RevenueFromRelatedParties_2_Q2_USD":0.0,"RevenueFromRelatedParties_1_Q2_USD":0.0,"PaymentsOfStockIssuanceCosts_2_Q2_USD":491000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":47871000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":42709000.0,"OperatingIncomeLoss_2_Q2_USD":-28814000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":27000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":407000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":5907000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-35693000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":46007892.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":46116175.0,"MarketableSecuritiesNoncurrent_0_Q2_USD":60006000.0,"LiabilitiesCurrent_0_Q2_USD":26125000.0,"AccountsPayableCurrent_0_Q2_USD":7642000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":57264000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":9751000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_2_Q2_pure":0.846,"ProceedsFromStockOptionsExercised_2_Q2_USD":1812000.0,"LongTermDebtNoncurrent_0_Q2_USD":21694000.0,"InterestExpenseDebt_2_Q2_USD":1300000.0,"InterestExpenseDebt_1_Q2_USD":600000.0,"OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_2_Q2_USD":0.0,"OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings_1_Q2_USD":0.0,"AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss_0_Q2_USD":93800000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":57264000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_2_Q2_pure":0.006,"StockIssuedDuringPeriodSharesStockOptionsExercised_2_Q2_shares":257834.0,"NumberOfOperatingSegments_2_Q2_Segment":1.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":1376000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":18669000.0,"NetIncomeLoss_2_Q2_USD":-36511000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":202315000.0,"RestrictedCashNoncurrent_0_Q2_USD":872000.0,"EarningsPerShareDiluted_1_Q2_USD":-0.13,"EarningsPerShareDiluted_2_Q2_USD":-0.79,"OperatingIncomeLoss_1_Q2_USD":-9805000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_2_Q2_USD":2200000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_1_Q2_USD":300000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":8128000.0,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":359788000.0,"PreferredStockSharesAuthorized_0_Q2_shares":10000000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":9859000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":5907000.0,"AmortizationOfDebtDiscountPremium_2_Q2_USD":300000.0,"AmortizationOfDebtDiscountPremium_1_Q2_USD":100000.0,"OperatingExpenses_2_Q2_USD":71523000.0,"OperatingExpenses_1_Q2_USD":37854000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":28049000.0,"ProfitLoss_2_Q2_USD":-36511000.0,"OtherLiabilitiesCurrent_0_Q2_USD":720000.0,"StockholdersEquity_0_Q2_USD":307500000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":193000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":285047000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_Q2_USD":-1194000.0,"DeferredRentCreditNoncurrent_0_Q2_USD":3432000.0,"IncreaseDecreaseInOtherOperatingLiabilities_2_Q2_USD":434000.0,"ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0_Q2_shares":4445.0,"DebtCurrent_0_Q2_USD":3125000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-264384000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-149760000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":3601000.0,"CommonStockSharesOutstanding_0_Q2_shares":46141454.0,"OtherLiabilitiesNoncurrent_0_Q2_USD":844000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-12382000.0,"Ticker":"STRO","CIK":"1382101","name":"SUTRO BIOPHARMA, INC.","OfficialName":"Sutro Biopharma Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"326059920.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210809"}]